Table 1 Baseline patient characteristics.

From: Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

Characteristic

TH arm (n = 114)

T-DM1 arm (n = 383)

Median age (IQR)

56 [47, 62]

56 [49, 63]

Age group (years)

 <50

41 (36%)

110 (29%)

 50−59

35 (31%)

127 (33%)

 60−69

30 (26%)

107 (28%)

 ≥70

8 (7%)

39 (10%)

Sex

 Male

1 (1%)

5 (1%)

 Female

113 (99%)

378 (99%)

Race

 White

93 (82%)

327 (85%)

 African American

7 (6%)

21 (5%)

 Asian

4 (4%)

22 (6%)

 Other

10 (9%)

13 (3%)

Ethnicity

 Hispanic or Latino

1 (1%)

11 3%)

 Non-Hispanic

97 (85%)

352 (92%)

 Ethnicity not known

16 (14%)

20 (5%)

Baseline LVEF

 50–55 (%)

14 (12%)

59 (15%)

 >55 (%)

100 (88%)

324 (85%)

BMI

 ≤25

42 (37%)

161 (42%)

 >25–30

33 (29%)

125 (33%)

 >30

39 (34%)

97 (25%)

  1. BMI body mass index, IQR intraquartile range, LVEF left ventricular ejection fraction, T-DM1 trastuzumab emtansine, TH paclitaxel with trastuzumab.
Back to article page